Inventurus Knowledge Solutions (IKS Health) has delivered yet another quarter of outstanding performance, with strong revenue growth, improved profitability, and operational excellence underscoring its leadership in technology-enabled healthcare services. Inventurus Knowledge Q2 FY26 results reflect robust execution, margin expansion, and a reaffirmation of its long-term strategic focus on AI-driven healthcare enablement. Notably, Rekha Jhunjhunwala and family are among the promoters of Inventurus Knowledge Solutions.
Inventurus Knowledge Q2 FY26: Quarterly Financial Performance
| Particulars | Q2 FY26 | Q1 FY26 | Q2 FY25 | YoY Change (%) | QoQ Change (%) |
|---|---|---|---|---|---|
| Revenue from Operations | 781.09 | 740.10 | INR 642.78 | +21.52 | +5.54% |
| EBITDA | I271.8 | 237.8 | 189.8 | +43.2 | +14.3% |
| EBITDA Margin (%) | 34.8 | 32.1 | 29.5 | +534 bps | +270 bps |
| PAT | 180.7 | 151.5 | 113.0 | +59.9 | +19.3% |
| PAT Margin (%) | 23.1 | 20.5 | 17.6 | +556 bps | +260 bps |
| ROE (%) | 29.6 | 31.0 | 23.2 | — | — |
| Earnings Per Share (EPS) | 10.8 | 9.1 | 6.8 | +59.0 | +19.2% |
Key Takeaways:
- Revenue Growth: 21.5% YoY increase, marking the company’s highest-ever quarterly revenue.
- Profit Surge: Net profit rose 59.9% YoY to INR 180.7 crore, driven by operational efficiency.
- Margin Expansion: EBITDA margin improved by 534 bps YoY, signaling scalability and disciplined cost control.
- Return Metrics: ROE at 29.6%, among the strongest in the small-cap IT services space.
Inventurus Knowledge H1 FY26: Half-Year Financial Snapshot
| Particulars | H1 FY26 | H1 FY25 | YoY Change (%) |
|---|---|---|---|
| Revenue from Operations | 1,521.2 | 1,282.9 | +18.6% |
| Adjusted EBITDA | 528.0 | 374.0 | +41.2% |
| EBITDA Margin (%) | 34.7 | 29.2 | +550 bps |
| PAT | 332.3 | 208.6 | +59.3% |
| PAT Margin (%) | 21.8 | 16.3 | +550 bps |
Key Takeaways:
- Sustained Growth: Revenue rose 18.6% YoY during H1 FY26.
- Operating Efficiency: EBITDA margin expanded to 34.7%, the highest in the company’s history.
- Profit Leverage: PAT growth of 59% YoY underscores robust cost management and technological leverage.
Operational Highlights
- Client Relationships: Over 450 enterprise-level customers, with 85% revenue from repeat clients.
- Workforce Strength: 12,940 employees as of 30 September 2025, including 2,228 clinically trained staff and 542 technology professionals.
- Key Deal Wins: Expanded partnerships with AdventHealth, Revere Health, and The Jackson Clinic, reinforcing IKS’s position in outcome-based healthcare solutions.
- AI Leadership: Launch of Agentic AI Platform on Google Cloud—80% of tasks handled autonomously, enhancing care delivery efficiency.
- Industry Recognition: Winner of Google Cloud 2025 DORA Award for “Augmenting Human Expertise with AI,” and ranked #1 in AI-driven RCM and Clinical Documentation by Black Book and KLAS Research.
Strategic Commentary
Sachin K. Gupta, Founder & Global CEO, stated:
“Inventurus Knowledge Q2 FY26 was a period of significant strategic execution and strong financial performance. Our results highlight the growing market demand for our Care Enablement Platform as healthcare systems increasingly seek integrated administrative, clinical, and financial solutions.”
Nithya Balasubramanian, Group CFO, added:
“Inventurus Knowledge Q2 FY26 performance—22% revenue growth, 43% EBITDA rise, and 60% PAT growth—reflects disciplined execution and operating leverage. Margin expansion demonstrates the scalability of our model and prudent capital management.”
Post-IPO Performance
| Metric | Detail |
|---|---|
| IPO Period | 12–16 December 2024 |
| Allotment Price | INR 1,329 |
| Listing Price | INR 1,960.85 (+47.54% premium) |
| Current Price (31 October 2025) | INR 1,646 (+23.9% over allotment price) |
| 52-Week High (26 December 2024) | INR 2,145.70 (+61.4% over allotment price) |
| IPO Size | INR 2,497.92 crore |
| Subscription | 52.68x oversubscribed |
Key Takeaways:
- The stock debuted with a 47.54% premium and remains 23.9% above its allotment price.
- Achieved a 61.4% peak gain post listing, signaling strong investor confidence.
- Current market capitalization stands at approximately INR 27,935 crore, positioning IKS as a high-growth small-cap IT leader.
Outlook
IKS Health is strategically positioned to sustain high growth through its outcome-based commercial model, integration of AI-driven automation, and deep client relationships. With a five-year sales CAGR of 46.5% and an operating profit CAGR of 42.3%, the company has demonstrated consistent execution excellence.
However, the stock’s premium valuation (P/E 55.4x; P/B 15.1x) demands continued operational consistency. The company’s focus on debt reduction, technology investments, and long-term platform partnerships should provide further support to its growth trajectory.
Conclusion
Inventurus Knowledge Solutions has cemented its position as one of the most dynamic players in the healthcare technology services space. Inventurus Knowledge Q2 FY26 results reaffirm its ability to combine high growth with expanding margins—a hallmark of scalable, efficient business models.
With consistent profitability, strong client stickiness, and accelerating AI-led innovation, IKS Health stands poised to continue delivering “Better, Safer, and More Efficient Healthcare” while driving superior value for stakeholders.
For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription stay tuned to IPO Central.